KinSea Lead Discovery AS

KinSea Lead Discovery AS is a new biotechnology start-up company developing marine bioactive compounds into pharmaceutically active products. To maximize the potential of marine natural products from the Arctic Ocean and bridge the gap between academia and industry, a drug discovery pipeline will be established. The therapeutic indications cover cancers as well as other diseases with high, unmet clinical need. With our first FLT3 inhibitor asset, which has successfully passed the animal proof-of-concept phase, we will develop a targeted therapy for hematologies. KinSea Lead Discovery AS is a pharmaceutical start-up company founded in September 2022 by UiT The Arctic University of Norway (UiT), the University of Bergen (UiB), Norinnova, and the Lead Discovery Center GmbH (LDC). Based in Tromsø, Norway, KinSea started operations in March 2023. Seed financing is secured through convertible loans from KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I), an early-stage life sciences venture fund based in Germany, and through Norinnova, UiT´s agency for research commercialization, with the purpose to expand the investor syndicate.

Nettsted

https://www.kinsea-lead-discovery.com/

Ekstern lenke til KinSea Lead Discovery AS

Bransje

Farmasøytisk produksjon

Bedriftsstørrelse

1 ansatt

Hovedkontor

Tromsø

Type

Privateid selskap

Grunnlagt

2022

Spesialiteter

drug discovery, natural compounds